RRC ID 37912
Author Subramanian N, Kanwar JR, Kanwar RK, Krishnakumar S.
Title Targeting Cancer Cells Using LNA-Modified Aptamer-siRNA Chimeras.
Journal Nucleic Acid Ther
Abstract Aptamers are chimerized with drug or antisense oligos or nanoparticles to generate targeted therapeutics for cancer. Aptamer chimerized siRNA rescues nonspecific delivery and, thereby, enhances the availability of siRNA to target cells. EpCAM RNA aptamer (EpApt or Ep) has potential for siRNA chimerization due to its secondary structure. Stathmin and survivin proteins are reported to aid oncogenicity in retinoblastoma (RB), breast cancer and other cancers. Thus, chimerization of EpCAM Apt with siRNA against survivin and stathmin, respectively, was performed by incorporating Locked Nucleic Acid (LNA) modification. The LNA-modified chimeric aptamers were stable until 96 h and got internalized into RB, WERI-Rb1 and breast cancer, MDAMB453 cell lines. The constructs were studied using the recombinant dicer enzyme for the siRNA generation. Quantitative polymerase chain reaction and immunofluorescence by microscopic analysis of chimeras in vitro exhibited silencing of stathmin and survivin in the RB and breast cancer model. The chimeric constructs showed significant inhibition of cell proliferation of breast cancer cells. Thus, LNA-modified aptamer-based siRNA delivery aids in cell targeting and necessitates further studies in animal models.
Volume 25(6)
Pages 317-22
Published 2015-12-1
DOI 10.1089/nat.2015.0550
PMID 26334953
MeSH Antigens, Neoplasm / genetics Aptamers, Nucleotide / genetics Aptamers, Nucleotide / therapeutic use* Cell Adhesion Molecules / genetics Cell Line, Tumor Epithelial Cell Adhesion Molecule Gene Silencing Humans Neoplasms / pathology* Oligonucleotides / genetics* RNA, Small Interfering / genetics*
IF 5.0
Times Cited 14
WOS Category MEDICINE, RESEARCH & EXPERIMENTAL CHEMISTRY, MEDICINAL BIOCHEMISTRY & MOLECULAR BIOLOGY
Resource
Human and Animal Cells WERI-Rb-1(RCB2146) MDA-MB-453(RCB1192)